Skip to content

Author

R. Lorenzon

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial.

BACKGROUND Type 1 diabetes results from immune-mediated destruction of pancreatic β cells, driven partly by regulatory T-cell (Treg) insufficiency. We previously showed that low-dose interleukin-2 (IL-2) selectively activates Tregs in people with type 1 diabetes. We aimed to evaluate the efficacy of low-dose IL-2 in pr...

M. Rosenzwajg, A. Hartemann, M. Halbron et al. · 1 citation
Open access Aug 2026

Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in immune-mediated inflammatory diseases.

Findings demonstrate that IL-2LD not only expands and activates Treg cells but also shapes an anti-inflammatory transcriptomic landscape characterised by ISG downregulation in Treg and Tconv cells.

N. Tchitchek, M. Rosenzwajg, R. Lorenzon et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.